Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclodextrins and oligonucleotide delivery to solid tumours.

Crispin R Dass1

  • 1Genetic Technologies Pty. Ltd., Hanover St 3065 Fitzroy Australia. crispin.dass@genetype.com.au

Journal of Drug Targeting
|June 19, 2004
PubMed
Summary

Cyclodextrins (CyDs) can potentially deliver therapeutic oligonucleotides to solid tumors. This review explores CyD properties and tumor barriers influencing oligonucleotide delivery for cardiovascular disease reversal.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metabolic reprogramming in head and neck cancer: therapeutic opportunities and challenges.

The Journal of pharmacy and pharmacology·2026
Same author

The role of PEDF in ageing and development: reduction of oxidative damage and support for stem cells.

The Journal of pharmacy and pharmacology·2025
Same author

From Carcinogenesis to Drug Resistance: The Multifaceted Role of Oxidative Stress in Head and Neck Cancer.

Cancers·2025
Same author

Key signalling pathways in head and neck squamous cell carcinoma: mechanisms and therapeutic targets.

The Journal of pharmacy and pharmacology·2025
Same author

Targeting metabolic vulnerabilities in breast cancer cells by combining PEDF and doxorubicin: pathway insights from GC/MS-based metabolomics.

EXCLI journal·2025
Same author

The Role of PEDF in the Eye, Bone, and Nervous and Immune Systems.

Pharmaceutics·2025

Area of Science:

  • Biotechnology and Pharmaceutical Sciences
  • Drug Delivery Systems
  • Oligonucleotide Therapeutics

Background:

  • Cyclodextrins (CyDs) are established excipients for solubilizing hydrophobic compounds in aqueous solutions.
  • Recent research highlights CyDs' role in cholesterol efflux, suggesting potential in cardiovascular disease (CVD) management.
  • Solid tumors present significant barriers to effective drug delivery, including poor penetration and cellular uptake.

Purpose of the Study:

  • To review the application of cyclodextrins for delivering therapeutic oligonucleotides to solid tumors.
  • To analyze the physicochemical properties of cyclodextrins relevant to oligonucleotide complexation and delivery.
  • To identify and discuss the barriers within the tumor microenvironment that impede oligonucleotide uptake.

Main Methods:

  • Literature review focusing on cyclodextrin properties and their interaction with oligonucleotides.
  • Analysis of solid tumor characteristics impacting drug delivery and cellular internalization.
  • Synthesis of existing knowledge on cyclodextrin-mediated drug delivery and oligonucleotide therapeutics.

Main Results:

  • Cyclodextrins exhibit versatile physicochemical properties suitable for forming complexes with oligonucleotides.
  • Solid tumor barriers, such as the extracellular matrix and poor vascularization, significantly challenge oligonucleotide delivery.
  • Understanding these interactions and barriers is crucial for optimizing cyclodextrin-based oligonucleotide delivery strategies.

Conclusions:

  • Cyclodextrins show promise as carriers for therapeutic oligonucleotides in solid tumor treatment.
  • Further research is needed to overcome tumor-specific delivery challenges and enhance oligonucleotide efficacy.
  • This approach could offer a novel strategy for treating cardiovascular diseases and other conditions treatable by oligonucleotide therapy.

Related Experiment Videos